Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Controlled Double-Blind Phase 3 Study to Assess Characteristics of S 303 Treated RBC Components and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia

NCT01716923 is registered in ClinicalTrials.gov with Cerus Corporation as lead sponsor.

NCT NCT01716923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01716923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Controlled Double-Blind Phase 3 Study to Assess Characteristics of S 303 Treated RBC Components and Evaluate Safety and Efficacy in Patients Requiring Transfusion Support of Acute Anemia
Lead sponsor
Cerus Corporation
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2013
Completion date
October 31, 2014
Enrollment
81 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

focus:use of s303 rbcs in patients with acute anemia